FDA Issues Fresh Criticism of Novo Nordisk Indiana Manufacturing Plant

November 24, 2025

Hype For Karuna’s Schizophrenia Drug Continues

March 29, 2023

AstraZeneca Invests $85M in Quell for “One and Done” Cell Therapy to Combat Type 1 Diabetes

June 13, 2023

Must Read

Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertising Claims

July 23, 2026

The End of Siloed Drug Development

July 23, 2026

Due to poor phase 2 data, Agios declares goodbye to the sickle cell program

July 23, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Due to poor phase 2 data, Agios declares goodbye to the sickle cell program

Novartis Lets Go of Phase 2 Radioligand Therapy Following Clinic Disappointment

Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

Ionis and AstraZeneca falter as the ATTR-CM medication fails Phase 3

GSK views the Hansoh-partnered ADCs’ phase 3 victory in China as confirming its “priority asset.”

Vogenx Files for a Nasdaq Capital Market IPO to Fund Metabolic Drug

AstraZeneca travels to China once more and purchases Dizal’s lung cancer medication for up to $1.5 billion

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

The End of Siloed Drug Development

Top 10 Reasons Commercial AI Requires Stronger Governance in Pharma

Top 10 Metrics Pharma Leaders Should Track During Digital Transformation

The Return of M&A as a Growth Strategy in Biopharma

Tag: reproxalap

FDA Issues Third Rejection for Aldeyra’s Reproxalap in Dry Eye Disease

Editor Picks

FDA Issues Fresh Criticism of Novo Nordisk Indiana Manufacturing Plant

Hype For Karuna’s Schizophrenia Drug Continues

AstraZeneca Invests $85M in Quell for “One and Done” Cell Therapy to Combat Type 1 Diabetes

Must Read

Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertising Claims

The End of Siloed Drug Development

Due to poor phase 2 data, Agios declares goodbye to the sickle cell program

Hot Topics

About Us

Follow Us